Tag Archive for: Clinical development

Rewind Therapeutics Strengthens Scientific Advisory Board with Leading International Neurology Experts as it Advances First-in-Class Remyelination Therapy

/in

Professors Shiv Saidha, Cristina Granziera, David Leppert, and Roberto Furlan are world-renowned experts in neuroimaging, multiple sclerosis (MS) biomarkers, neuroimmunology, and translational drug development Appointments strengthen Rewind’s clinical experience as its GPR17 remyelination therapy advances toward clinical trials Leuven, Belgium – 18 June 2025 – Rewind Therapeutics, which is developing first-in-class treatments for demyelination-associated diseases, […]

Read more

DelSiTech Announces Closing of EUR 10 Million Financing Round to Advance its Silica-Based Drug Delivery Technology Platform

/in

New investment from DRW Venture Capital LLC and Tolmar International Ltd Funds will be used to advance its proprietary, silica-based, drug delivery technology platform towards the clinic and further build DelSiTech Turku, Finland – 16th January 2024. Clinical-stage drug delivery and development company DelSiTech, today announces the successful completion of a EUR 10 million financing round, the […]

Read more

Versameb Appoints Professor Roger Dmochowski as Chief Medical Officer

/in

Professor Dmochowski is a world leading key opinion leader in female urology and urologic reconstruction Versameb is accelerating preparations for IND filing of lead candidate VMB-100 Versameb AG (“Versameb”), a pre-clinical stage company focused on discovering and developing innovative RNA-based therapeutics, is pleased to announce the appointment of Professor Roger Dmochowski as Chief Medical Officer […]

Read more

InProTher announces EUR 6MSeed financing with the participation of the European Innovation Council Fund to develop first-in-class cancer immunotherapy

/in

• Danish start-up developing immunotherapies designed to fight the tumors from within • Financing supports GMP and tox studies and will advance InProTher’s first-in-class cancer immunotherapy into First-in-Human clinical trials • Strengthens team with appointment of industry heavyweights Dr. Sven Rohman as Chairman and Dr. Hamina Patel as CMO Copenhagen, Denmark, 24 May 2023: InProTher, an early-stage biotechnologycompany developing effective immunotherapies targeting the Human Endogenous Retroviruses (HERVs), today announces that it has raised EUR 6M of Seed funding from private investors with the participation of the European Innovation Council (EIC) Fund. The financing will enable InProTher to advance its lead drug […]

Read more

Granular Therapeutics to accelerate development of next-generation pipeline for treating mast cell driven diseases

/in

Clinical candidate selection finalised for lead programme targeting mast-cell driven diseases  Dermatology industry veteran Thibaud Portal, PhD appointed as CEO   London, UK, March 30, 2023 – Granular Therapeutics, (Granular) a private biotech company specialising in precision biologic therapies for treating mast cell driven disorders, today announces clinical candidate selection for its lead programme which […]

Read more